The Curcumin Analog PAC Is a Potential Solution for the Treatment of Triple-Negative Breast Cancer by Modulating the Gene Expression of DNA Repair Pathways.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Jun 2023
Historique:
received: 28 04 2023
revised: 24 05 2023
accepted: 30 05 2023
medline: 12 6 2023
pubmed: 10 6 2023
entrez: 10 6 2023
Statut: epublish

Résumé

Breast Cancer (BC) is one of the most common and challenging cancers among females worldwide. Conventional treatments for oral cancer rely on the use of radiology and surgery accompanied by chemotherapy. Chemotherapy presents many side effects, and the cells often develop resistance to this chemotherapy. It will be urgent to adopt alternative or complementary treatment strategies that are new and more effective without these negative effects to improve the well-being of patients. A substantial number of epidemiological and experimental studies reported that many compounds are derived from natural products such as curcumin and their analogs, which have a great deal of beneficial anti-BC activity by inducing apoptosis, inhibiting cell proliferation, migration, and metastasis, modulating cancer-related pathways, and sensitizing cells to radiotherapy and chemotherapy. In the present study, we investigated the effect of the curcumin-analog PAC on DNA repair pathways in MCF-7 and MDA-MB-231 human breast-cancer cell lines. These pathways are crucial for genome maintenance and cancer prevention. MCF-7 and MDA-MB-231 cells were exposed to PAC at 10 µM. MTT and LDH assays were conducted to evaluate the effects of PAC on cell proliferation and cytotoxicity. Apoptosis was assessed in breast cancer cell lines using flow cytometry with annexin/Pi assay. The expression of proapoptotic and antiapoptotic genes was determined by RT-PCR to see if PAC is active in programming cell death. Additionally, DNA repair signaling pathways were analyzed by PCR arrays focusing on genes being related and confirmed by quantitative PCR. PAC significantly inhibited breast-cancer cell proliferation in a time-dependent manner, more on MDA-MB-231 triple-negative breast cancer cells. The flow cytometry results showed an increase in apoptotic activity. These data have been established by the gene expression and indicate that PAC-induced apoptosis by an increased Bax and decreased Bcl-2 expression. Moreover, PAC affected multiple genes involved in the DNA repair pathways occurring in both cell lines (MCF-7 and MDA-MB231). In addition, our results suggest that PAC upregulated more than twice 16 genes (ERCC1, ERCC2, PNKP, POLL, MPG, NEIL2, NTHL1, SMUG1, RAD51D, RAD54L, RFC1, TOP3A, XRCC3, XRCC6BP1, FEN1, and TREX1) in MDA-MB-231, 6 genes (ERCC1, LIG1, PNKP, UNG, MPG, and RAD54L) in MCF-7, and 4 genes (ERCC1, PNKP, MPG, and RAD54L) in the two cell lines. In silico analysis of gene-gene interaction shows that there are common genes between MCF-7 and MDA-MB-321 having direct and indirect effects, among them via coexpression, genetic interactions, pathways, predicted and physical interactions, and shared protein domains with predicted associated genes indicating they are more likely to be functionally related. Our data show that PAC increases involvement of multiple genes in a DNA repair pathway, this certainly can open a new perspective in breast-cancer treatment.

Identifiants

pubmed: 37298600
pii: ijms24119649
doi: 10.3390/ijms24119649
pmc: PMC10253416
pii:
doi:

Substances chimiques

Curcumin IT942ZTH98
Antineoplastic Agents 0
ERCC2 protein, human EC 5.99.-
Xeroderma Pigmentosum Group D Protein EC 3.6.4.12
PNKP protein, human EC 2.7.1.-
Phosphotransferases (Alcohol Group Acceptor) EC 2.7.1.-
DNA Repair Enzymes EC 6.5.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deanship for Scientific Research at Imam Mohammed Ibn Saud Islamic University
ID : RP-21-09-87

Références

DNA Repair (Amst). 2013 Aug;12(8):620-36
pubmed: 23684800
Sci Rep. 2021 Jun 3;11(1):11701
pubmed: 34083581
J Mol Histol. 2006 Sep;37(5-7):225-38
pubmed: 16855787
Cancer Sci. 2014 Apr;105(4):370-88
pubmed: 24484288
Mol Oncol. 2017 Jun;11(6):640-654
pubmed: 28371273
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6090-5
pubmed: 10339546
Cell Biochem Biophys. 2015 Nov;73(2):381-387
pubmed: 27352326
Cancer Lett. 2018 Jun 28;424:119-126
pubmed: 29574277
Nucleic Acids Res. 2012 Jul;40(13):6016-25
pubmed: 22447450
CA Cancer J Clin. 2006 May-Jun;56(3):168-83
pubmed: 16737949
Cancer Lett. 2012 Dec 31;327(1-2):73-89
pubmed: 22252118
Cancer Lett. 2008 Aug 18;267(1):133-64
pubmed: 18462866
J Nat Prod. 2016 Mar 25;79(3):629-61
pubmed: 26852623
Anticancer Drugs. 2005 Mar;16(3):263-75
pubmed: 15711178
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Mutat Res. 2021 Jan-Jun;822:111727
pubmed: 33220551
BMC Cancer. 2006 Oct 09;6:243
pubmed: 17029639
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Nat Rev Cancer. 2015 Mar;15(3):166-80
pubmed: 25709118
Clin Cancer Res. 2019 Feb 1;25(3):977-988
pubmed: 29980530
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70
pubmed: 9861027
J Biol Chem. 2007 Sep 28;282(39):28609-28618
pubmed: 17684018
Pol J Pathol. 2018;69(1):73-81
pubmed: 29895130
Cells. 2023 Feb 11;12(4):
pubmed: 36831255
Oncogene. 2020 Jan;39(1):234-247
pubmed: 31471584
Mol Carcinog. 2016 Mar;55(3):233-44
pubmed: 25641341
Clin Cancer Res. 2002 Jul;8(7):2286-91
pubmed: 12114432
J Cancer. 2019 Jun 2;10(13):2969-2981
pubmed: 31281474
Front Oncol. 2018 Dec 11;8:614
pubmed: 30619754
Anticancer Drugs. 2009 Jul;20(6):444-9
pubmed: 19384191
Clin Cancer Res. 2007 Jan 1;13(1):260-7
pubmed: 17200364
Anticancer Res. 2018 Jan;38(1):131-136
pubmed: 29277765
Sci Rep. 2021 Jun 22;11(1):13087
pubmed: 34158560
Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):1-6
pubmed: 18439063
Arch Oral Biol. 2022 Sep;141:105498
pubmed: 35810494
Nat Rev Drug Discov. 2010 Feb;9(2):117-28
pubmed: 20081869
Nature. 2009 Oct 22;461(7267):1071-8
pubmed: 19847258
Front Pharmacol. 2021 Feb 08;11:629266
pubmed: 33628188
N Engl J Med. 2013 Mar 21;368(12):1101-10
pubmed: 23514287
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Clin Cancer Res. 2008 Jul 1;14(13):4345-52
pubmed: 18594018
Ann N Y Acad Sci. 2005 Nov;1056:206-17
pubmed: 16387689
BMC Cancer. 2003 Mar 4;3:6
pubmed: 12614485
Nat Genet. 2019 Apr;51(4):649-658
pubmed: 30926972
Arch Pharm (Weinheim). 2004 Jan;337(1):42-54
pubmed: 14760627
BMC Cancer. 2016 Jul 27;16:540
pubmed: 27465411
Int J Gen Med. 2021 Oct 07;14:6477-6485
pubmed: 34675615
BMC Biol. 2020 Mar 30;18(1):36
pubmed: 32228693
Klin Onkol. 2021 Winter;34(1):26-32
pubmed: 33657816
Nat Rev Cancer. 2008 Mar;8(3):193-204
pubmed: 18256616
Biomolecules. 2022 Jul 20;12(7):
pubmed: 35883563
EBioMedicine. 2016 Dec;14:32-43
pubmed: 27852524
DNA Repair (Amst). 2020 Sep;93:102920
pubmed: 33087284
Arch Oral Biol. 2021 Sep;129:105200
pubmed: 34146926
J Ovarian Res. 2016 Jun 18;9(1):35
pubmed: 27315793
Oncogene. 1999 Jun 3;18(22):3427-30
pubmed: 10362365
Cancer Discov. 2014 Oct;4(10):1140-53
pubmed: 25096233
Oncogene. 2021 Oct;40(40):5893-5901
pubmed: 34363023
Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S56-71
pubmed: 17884153
Mol Pharmacol. 2008 Aug;74(2):505-16
pubmed: 18477668
Cancer Cell. 2019 Feb 11;35(2):256-266.e5
pubmed: 30753826
Front Genet. 2015 Apr 23;6:157
pubmed: 25954303
Breast Cancer Res Treat. 2011 Jul;128(1):97-107
pubmed: 20680677
Ann Transl Med. 2014 Apr;2(4):32
pubmed: 25333008
Oxid Med Cell Longev. 2016;2016:1546392
pubmed: 27042257
Mol Genet Genomic Med. 2019 Sep;7(9):e852
pubmed: 31328431

Auteurs

Esraa Almalki (E)

Department of Biochemistry, College of Sciences, King Saud University, Riyadh 11451, Saudi Arabia.

Abdullah Al-Amri (A)

Department of Biochemistry, College of Sciences, King Saud University, Riyadh 11451, Saudi Arabia.

Reem Alrashed (R)

Department of Biochemistry, College of Sciences, King Saud University, Riyadh 11451, Saudi Arabia.

Mohamed Al-Zharani (M)

Biology Department, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia.

Abdelhabib Semlali (A)

Groupe de Recherche en Écologie Buccale, Faculté de Médecine Dentaire, Université Laval, Québec, QC G1V 0A6, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH